FMP

FMP

Enter

ETON - Eton Pharmaceuticals...

photo-url-https://images.financialmodelingprep.com/symbol/ETON.png

Eton Pharmaceuticals, Inc.

ETON

NASDAQ

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

12.45 USD

0.48 (3.86%)

Free Cash Flow

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

34.03M

49.06M

67.81M

76.69M

66.32M

79.92M

96.3M

116.04M

139.82M

168.48M

Revenue %

-

44.19

38.22

13.1

-13.52

20.5

20.5

20.5

20.5

Operating Cash Flow

-10.22M

-5.75M

985.58k

-11.28M

-4.4M

-9.85M

-11.87M

-14.3M

-17.23M

-20.77M

Operating Cash Flow %

-30.02

-11.72

1.45

-14.71

-6.63

-12.33

-12.33

-12.33

-12.33

Cap Ex

-2.62M

-3.29M

-8.98M

-4.33M

-2.6M

-5.95M

-7.17M

-8.64M

-10.41M

-12.54M

Cap Ex %

-7.71

-6.71

-13.24

-5.64

-3.92

-7.44

-7.44

-7.44

-7.44

Free Cash Flow

-12.84M

-9.04M

-7.99M

-15.61M

-7M

-15.8M

-19.04M

-22.94M

-27.64M

-33.31M

Weighted Average Cost Of Capital

Price

0.15

Beta

Diluted Shares Outstanding

25.33M

Costof Debt

7.57

Tax Rate

After Tax Cost Of Debt

7.57

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

35M

Total Equity

3.75M

Total Capital

38.75M

Debt Weighting

90.33

Equity Weighting

9.67

Wacc

7.33

Build Up Free Cash Flow

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

34.03M

49.06M

67.81M

76.69M

66.32M

79.92M

96.3M

116.04M

139.82M

168.48M

Operating Cash Flow

-10.22M

-5.75M

985.58k

-11.28M

-4.4M

-9.85M

-11.87M

-14.3M

-17.23M

-20.77M

Cap Ex

-2.62M

-3.29M

-8.98M

-4.33M

-2.6M

-5.95M

-7.17M

-8.64M

-10.41M

-12.54M

Free Cash Flow

-12.84M

-9.04M

-7.99M

-15.61M

-7M

-15.8M

-19.04M

-22.94M

-27.64M

-33.31M

Wacc

7.33

7.33

7.33

7.33

7.33

Pv Lfcf

-14.72M

-16.53M

-18.55M

-20.83M

-23.39M

Sum Pv Lfcf

-94.02M

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

7.33

Free Cash Flow T1

-33.97M

Terminal Value

-637.47M

Present Terminal Value

-447.58M

Intrinsic Value

Enterprise Value

-541.6M

Net Debt

29.28M

Equity Value

-570.87M

Diluted Shares Outstanding

25.33M

Equity Value Per Share

-22.54

Projected DCF

-22.54 1.007%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep